Embelia

Other Names

AembillaAmbtiAmodhaAmoghaAnthunashanaAntidesma grossularia Raeusch.Antidesma ribes (Burm.f.) Raeusch.Ardisia tenuiflora BlumeBaavdingaBab-o rangBabadingBaberangBabrungBai hua suan guo tengBaibadangBaibidangBaibirangBaobadangBaobarangBhabhirangaBhai-birrungBhasmakaBidangBidangaBirangaCalispermum scandens Lam.ChibatandulaChitraChitraBijaChitratandulaChu PreukCitrabijaCitratandulaEmbelia burmanni Retz.Embelia dentata Buch.-Ham. ex Wall.Embelia garciniaefolia Miq.Embelia garciniifolia (Wall. ex A.DC.) Miq.Embelia garciniifolia Wall. ex Ridl.Embelia glandulifera WightEmbelia indica J.F.Gmel.Embelia paniculata MoonEmbelia ribesEmbelia ribes Burm.f.Embelia ribes subsp. ribesEmbelia ribes var. garciniifolia Wall. ex A.DC.Embelia ribes var. ribesEmbelia ribes var. sillettensis A.DC.Embelia robusta C.B.ClarkeEmbelia robusta Roxb.Embelia sumatrana Miq.Embelia tsjeriam-cottam (Roem. & Schult.) A.DC.Embelia tsjeriam-cottam A.DC.Embelia tsjeriamcottam A.DC.False black pepperGaharaGahvaraGardabhaGhoshaHulimeeseJantughnaJantughniJantuhantriJantunashakaJantunashanKairalaKairaliKapaliKarkannieKarkunnieKevalaKiritaKrimighnaKrimihaKrimikantakaKrimiripuKrimishetruKrmighnaKrmiripuMoghaMrigagaminiPavakaRasayanaRibesiodes garciniifolium (Wall. ex A.DC.) KuntzeRibesiodes ribes (Burm.f.) KuntzeRibesiodes robusta KuntzeRibesiodes robustum (Roxb.) KuntzeSamara ribes (Burm.f.) Benth. & Hook.f. ex KurzSamara robusta (Roxb.) KurzSangkongShudratandulaSuchitrabijaSucitrabijaSweta TandulaTandulaTundulaTunduliyakaVaayu vilangaVai vidangVaividangVaraVatariVavadingVavaringVavdingVayavadangVayavidangaVayu-vilamgamVayuvidangaVayuvidangaluVayuvidangamVayuvidangamuVayuvilangaVayuvilangamVellaVellahVellalVidangVidangaVidangahVidangamVidangamuVijhalaVilalVilangaVilangamuVitankamVivilangamVizhalVizhalariVollaiVrishanashanaVrishnasanaVyivilangamuVyvirangWawrungWhite-flowered embeliaWhiteflower embelia

Synopsis

Embelia (Embelia ribes Burm.f.)

1. Identity and Botanical Description

1.1 Taxonomic and Chemical Names

Embelia ribes Burm.f. belongs to the family Myrsinaceae (now frequently reclassified within Primulaceae) and is commonly known in Ayurveda as Vidanga. It is also widely known as false black pepper or Vidanga. In various regional languages of the Indian subcontinent it carries the names Vayuvidangalu or Vayulavangalu (Telugu), Vayu Vilanga (Tamil), Vilal (Malayalam), Vavaring (Punjabi), Baobarang (Urdu), Ambati/Kokla (Marathi), Bidanga (Oriya), and Vavading (Gujarati).

The principal bioactive compound, embelin, carries the systematic chemical name 2,5-dihydroxy-3-undecyl-1,4-benzoquinone and is a natural benzoquinone isolated from the fruit of Embelia ribes. Embelin, a benzoquinone originally isolated from fruits of Embelia ribes Burm.f. (Myrsinaceae), is also a phytochemical constituent of Ardisia japonica and Oxalis erythrorhiza.

1.2 Plant Morphology and Natural Habitat

The plant is a large, scandent, struggling, medicinal climbing shrub belonging to the family Myrsinaceae. It is an evergreen climber capable of growing to 15 m. It is a member of the Myrsinaceae family that grows in hilly areas of India up to 1,500 metres in elevation, from the outer Himalayas to the Western Ghats. It is an Indo-Malaysian species, extensively used in various traditional medicine systems for treating various diseases.

The bright orange hydroxybenzoquinone embelin-rich fruits of E. ribes have become popular in ethnomedicine. Almost all parts of E. ribes — stem, leaves, roots, seeds, and bark — possess medicinal properties.

1.3 Conservation Status

Due to overexploitation of this plant, it is reported in the Red List Data Book as vulnerable. Vaibidang (Embelia ribes) is crucial in Ayurvedic formulations, used in approximately 75 preparations, and this climbing shrub is red-listed, found in semi-evergreen forests across Asia, particularly India. At the state level in India, it holds Vulnerable status in Karnataka, Nagaland, Orissa, and Sikkim; Near Threatened in Arunachal Pradesh and Kerala; and Critically Endangered in Andhra Pradesh, reflecting regional variations in threat levels. Unsustainable harvesting and habitat loss threaten E. ribes populations, with conservation advocates calling for research into in vitro propagation. Misidentification and adulteration in the market further threaten the survival of E. ribes.

1.4 Common Forms and Preparations

In India, Embelia ribes has a long history of use in the Ayurvedic system of medicine in various forms including churna (powder), asava (fermented liquid), aristha (herbal wine), lauha (iron-based preparation), bati (tablet), and taila (medicated oil). It is widely used in Ayurveda for its rejuvenating property in the preparation of classical formulations such as panchanimbadivati, sanjivanivati, and chandraprabhavati. In Ayurveda, it is considered broadly beneficial across a variety of diseases, and is also used in Homeopathy.

2. Traditional and Historical Use

2.1 Ayurvedic Tradition

References to Embelia ribes date back to classical Ayurvedic texts such as the Charaka Samhita (circa 2nd century CE) and the Sushruta Samhita, where Vidanga is praised under the category of anti-krimi (anti-parasitic) remedies. Embelia ribes Burm.f., also known as Vidanga, is one of the oldest herbs in Indian traditional medicine.

Ancient healers recommended Vidanga phala (fruit) powder for intestinal worms and pinworms, believing its tikta-kashaya (bitter-astringent) taste would repel toxins and parasites. Ayurveda describes Vidanga as pungent, causing increase in digestive fire, and curing flatulence and colic.

It has always been a significant part of Ayurvedic medical history in various forms, and has been extensively used as a curative agent for stomach aches, leprosy, nervous debility, dyspepsia, flatulence, colic tumors, asthma, fever, ascaris infestation, and skin diseases.

In medieval herbal treatises such as the Bhavaprakasha, Vidanga is described as manjari rakta chitra (cluster of red spots), symbolizing its rich color. Over the centuries, regional folk healers in Kerala developed oil preparations (Vidanga Taila) combining Vidanga powders with sesame oil for topical fungal infections and scalp conditions.

2.2 Traditional Preparations and Specific Uses

It is an endangered medicinal plant valued for its digestive, carminative, anthelmintic, and laxative properties since time immemorial, and is also used in diabetes, heart-related problems, neural disorders, cancerous tumors, and liver disorders. The seeds are also used for wound healing, antioxidant, anti-inflammatory, analgesic, and contraceptive activity.

In Ayurveda, it is used to cure skin diseases, abdominal pains, flatulence, worms, mental disorders, tumors, bronchitis, jaundice, and cardio disorders. Medicated oil prepared with Vidanga is used as Nasya (nasal administration) in sinusitis, chronic rhinitis, headaches, and migraine; external massage of the forehead with Vidanga-based preparations is also traditionally recommended for headache relief.

Traditionally, a decoction of the plant along with Anantamoola (Hemidesmus indicus) is administered in cases of cervical lymphadenitis (Gandamala), while a paste prepared with cold water is applied externally over swollen glands.

3. Key Constituents and Active Compounds

3.1 Primary Phytochemicals

E. ribes is high in essential oils, alkaloids, flavonoids, steroids, and phenolics, all of which have medicinal benefits.

The main chemical constituent of E. ribes is embelin, and other chemical constituents include volatile oils, tannins, christembine, resinol, embeliol, embelinol, quercitol, vilangin, potassium embelate, aryl-substituted benzoxadiazine, 5-O-ethylembelin, and 5-O-methylembelin (derivatives).

Berries of Embelia ribes contain chemical constituents including embelin, volatile oil, fixed oil, resin, tannin, christembine, and phenolic acids such as caffeic acid, vanillic acid, chlorogenic acid, cinnamic acid, and o-coumaric acid; approximately 4.33% of the embelin content is observed within the berries.

Phytochemical investigation of the seeds resulted in the isolation of three new compounds identified as embelinol (1), n-pentacosanyl-n-nonadeca-7'-en-9'-alpha-ol-1'-oate (embeliaribyl ester) (2), and 1,2,4,5-tetrahydroxy 3-undecanyl benzene (embeliol) (3), along with the known compound 2,5-dihydroxy-3-undecyl-2,5-cyclohexadiene-1,4-dione (embelin) (4).

3.2 Embelin: The Principal Bioactive Compound

Embelin is a plant-based benzoquinone and the major active constituent of the fruits of Embelia ribes Burm. The hydrophobic nature of embelin leads to poor absorption and limits its therapeutic potential — a challenge that has motivated the development of nanoformulation delivery systems. These nanocarriers include polymeric nanoparticles, liposomes, nanostructured lipid carriers, micelles, nanoemulsion, and metallic nanoparticles.

3.3 Other Notable Constituents

Vilangin, another constituent identified from Embelia ribes and E. robusta, was reported as a new constituent in Current Science (1961). Methanolic extract of berries from one accession exhibited the highest total phenolic content (18.18 ± 0.14 mg GAE/g DW), whereas ethanolic extract showed the highest total flavonoid content (8.35 ± 0.20 mg RE/g DW).

4. Mechanisms of Action

4.1 XIAP Inhibition and Apoptotic Signaling

Embelin is a small-molecule inhibitor of X-linked inhibitor of apoptosis protein (XIAP), and it induces apoptosis in tumor cells via the inhibition of XIAP. Embelin is a potent small molecule inhibitor of XIAP, which prevents the binding of XIAP to procaspase-9, and exhibits cytotoxic effects via suppressing the activity of various signaling cascades including PI3-kinase/AKT in a variety of cancer cell lines.

4.2 NF-κB Pathway Suppression

Embelin, primarily identified from the Embelia ribes plant, has been shown to exhibit chemopreventive, anti-inflammatory, and apoptotic activities. Because nuclear factor-kappaB (NF-κB) regulates several genes associated with inflammation, proliferation, carcinogenesis, and apoptosis, researchers postulated that embelin mediates its activity through modulation of NF-κB activation; it was found that embelin inhibited tumor necrosis factor (TNF) alpha-induced NF-κB activation. Embelin was found to inhibit sequentially the TNFα-induced activation of the inhibitory subunit of NF-κBα (IκBα) kinase, IκBα phosphorylation, IκBα degradation, and p65 phosphorylation and nuclear translocation.

4.3 p38 MAPK / JNK and Oxidative Stress Pathways

Treatment of A549 lung cancer cells with embelin resulted in enhancement of phospho-p38 and phospho-JNK levels as early as 4 hours; pretreatment with specific inhibitors of p38 and JNK abrogated embelin-induced caspase-3 activation. Embelin inactivates NF-κB by inhibiting nuclear transportation of p65 and has also been shown to inhibit STAT3 phosphorylation by inducing the expression of PTEN.

4.4 Anti-inflammatory Action via TNF-α and Eicosanoid Pathways

Inflammation is regulated by the pleiotropic pro-inflammatory cytokine TNF-α, whose production has been implicated in neurodegeneration and cancer. Several studies have shown that the anti-inflammatory activity of embelin is mediated by reduction in TNF-α. Molecular docking and experimental approaches demonstrated that embelin is a potential inhibitor of TNF-α converting enzyme (TACE).

4.5 Antiangiogenic Action

The benzoquinone embelin is a weak mitochondrial uncoupler that prevents neoangiogenesis during tumor growth and wound healing by exhausting the low respiratory reserve of proliferating endothelial cells without adversely affecting quiescent endothelial cells.

4.6 GABAergic Mechanism (CNS Effects)

The anxiolytic and antidepressant activity of embelin is proposed to be due to an antagonistic effect on the GABA receptor complex, as most anxiolytic and antidepressant molecules selectively bind to the high-affinity benzodiazepine binding site present on the GABA receptor. Embelin possesses the features of a compound that can traverse the blood-brain barrier (BBB) and prompt a reaction in the CNS.

5. Scientific Evidence by Area of Use

5.1 Antiparasitic / Anthelmintic Activity

Evidence strength: Moderate (animal and in vitro; limited human data within multi-herb compositions)

Embelin exhibits a range of activities including anthelmintic (Bøgh et al., 1996). Studies on the Ethiopian medicinal plant Embelia schimperi demonstrated that embelin, in both its crude hydroalcoholic extract form and as a diammonium salt, possesses anthelmintic properties against intestinal parasites such as the dwarf tapeworm and hookworm, and showed significant rates of parasite clearance in both in vivo and in vitro models. Research on the seeds of E. ribes has shown the strong anthelmintic effects of aqueous and alcoholic extracts against parasites such as Haemonchus contortus in sheep, demonstrating the effectiveness of embelin in fighting helminthic infections.

One notable human study involved a multi-herb formulation. Pippalyadi yoga, a composite drug containing Piper longum, Embelia ribes, and borax in equal amounts, was investigated in 254 women covering 4,694 cycles; oral administration of the drug at a dose of 1 gm/day gave reported good results, with drug failure in only 4 women and pregnancy due to drug omission in 26 women; minor side effects were observed in 17 cases. These data, however, pertain to the antifertility use of the composite and do not isolate E. ribes alone.

5.2 Anticancer Activity

Evidence strength: Preclinical only (in vitro cell lines, animal models); no clinical human trials identified

In one study investigating the anticancer effect of embelin on human gastric carcinoma cells (SGC7901), cell proliferation was measured using MTT assay following treatment with embelin at concentrations of 5, 10, and 15 µM on days 1, 3, and 5. Treatment with embelin decreased cell proliferation, induced caspase-3 activation, and suppressed NF-κB p65 activation; embelin also reduced p-IκBα and p-IKKα/β protein expression levels. The study concluded that embelin induces cell apoptosis in human gastric carcinoma through activation of p38 MAPK and inhibition of NF-κB signaling pathways.

A separate investigation of embelin in human gastric cancer cells found that embelin reduced cancer cell viability, induced apoptosis, and enhanced 5-FU antitumor activity. Mechanistically, embelin induced cell cycle arrest at the S and G2/M phases and downregulated expression of XIAP and cell cycle-regulatory proteins including CDK1, CDC25B, CDC25C, cyclin B1, and CDK2.

In the context of glioma, embelin was identified as a novel XIAP inhibitor from Embelia ribes with anti-inflammatory and anti-cancer activities. The study found that embelin suppressed proliferation of human glioma cells but not in normal immortalized human astrocytes, and that embelin induced apoptosis in human glioma cells by inhibiting NF-κB.

In vitro results showed that co-treatment of embelin and adenoviral TRAIL synergistically suppressed the proliferation of acute myeloid leukemia cells, with embelin demonstrating the ability to enhance TRAIL-induced apoptosis and activate the caspase pathway.

In vitro studies further revealed that embelin inhibits malignant properties of breast cancer cells through inactivation of metastatic signaling molecules including MMPs, VEGF, and hnRNP-K.

All anticancer evidence is from cell-line and animal studies. No human clinical trials of embelin in cancer have been identified in the peer-reviewed literature.

5.3 Antidiabetic and Antidyslipidemic Activity

Evidence strength: Preclinical only (animal models); no human clinical trials

A single study has reported the antihyperglycemic activity of a decoction of E. ribes in glucose-induced hyperglycemic albino rabbits. The lipid-lowering and antioxidant potential of ethanolic extract of E. ribes was investigated in streptozotocin (40 mg/kg IV, single injection)-induced diabetes in rats; twenty days of orally feeding the extract at 200 mg/kg to diabetic rats resulted in significant (P < 0.01) decrease in blood glucose, serum total cholesterol, and triglycerides, and increase in HDL-cholesterol levels compared to pathogenic diabetic rats.

A separate study was undertaken to investigate the modulatory effect of 6 weeks' chronic oral administration of E. ribes ethanolic extract on diabetes induced by streptozotocin (STZ), with reference to changes in glucose levels, glycated haemoglobin status, and cardiac toxicity; STZ treatment (40 mg/kg IV) resulted in significant increase in blood glucose levels, glycated haemoglobin levels, heart rate, and systolic blood pressure.

The derivatives of embelin, 6-bromoembelin and vilangin, also improved diabetic conditions and ameliorated body weight changes due to diabetes. A systematic review and meta-analysis supports scientific evidence for the antidiabetic activity of E. ribes/embelin/derivatives of embelin; however, further research is warranted in clinical trials to validate these findings.

5.4 Central Nervous System Activity

Evidence strength: Preclinical only (animal and zebrafish models); no human clinical trials

It is well-reported that embelin exhibits strong anticonvulsant, anxiolytic, and antidepressant properties, and may also improve conditions like sickness behavior, Huntington's disease, multiple sclerosis, cerebral ischemia, and traumatic brain injury.

In one study, animals treated with diazepam (1 mg/kg) and embelin (2.5 and 5 mg/kg) showed significant (P < 0.05 and P < 0.001) increases in time spent in the lighted box in a light-dark box anxiety model. This led to the conclusion that embelin exhibits significant anxiolytic activity in a dose-dependent manner.

Earlier findings reported that embelin significantly inhibited seizures induced by electroshock and pentylenetetrazole (PTZ) in a dose-dependent manner.

Embelin's ability to protect neurons against 3-NP-induced Huntington's disease-like pathology in rats was examined, in which embelin was pretreated in adult Wistar rats at doses of 10 and 20 mg/kg p.o. for a week; embelin significantly reversed behavioral changes, improved antioxidant status, and repaired striatal neuronal damage brought on by 3-nitropropionic acid.

Embelin possesses properties of a compound that can traverse the blood-brain barrier. Nevertheless, at the time of one systematic review, there had been no published studies of its neuropharmacological activities against Alzheimer's disease-like conditions, prompting a specific rat study of anti-amnesic potential in scopolamine-induced cognitive impairment.

Critically, although a vast number of activities have been reported with embelin in experimental settings, there is not a single human study found on embelin related to CNS activity.

5.5 Cardioprotective Activity

Evidence strength: Preclinical only (animal models)

Additional studies highlight the potential cardioprotective effects of embelin against myocardial injury, emphasizing its role in reducing oxidative stress, apoptosis, and cardiotoxicity, thus suggesting its therapeutic benefits in heart conditions. Bhandari et al. reported the cardioprotective activity of the aqueous extract of Embelia ribes in isoproterenol-induced myocardial infarction in albino rats. All published evidence in this area remains at the animal model level.

5.6 Antifertility / Contraceptive Activity

Evidence strength: Animal models and limited early-phase human studies (multi-herb formulations)

Studies in female rats examined the antifertility effects of Embelia ribes berries, its various extracts, and embelin as the putative active principle; when incorporated into the diet at both 10% and 20% dose levels, 62% antifertility activity was observed in treated animals. In the majority of these animals, the diestrous phase was prolonged within 2 weeks of treatment; however, no dose-duration effect was observed.

Embelin extracted from Embelia ribes berries altered testicular histology and glycogen, gametogenic counts, and accessory sex gland fructose at dose levels of 0.3, 0.4, and 0.5 mg/kg body weight administered subcutaneously for 35 days. The compound is suggested to possess anti-androgenic activity.

Clinical trials were conducted with Vidangdi yoga — an herbal preparation containing Embelia ribes seeds, Hibiscus rosa-sinensis flowers, and Ferula foetida oleo-gum resin — for its antifertility activity; the drug was found to be very effective and showed no toxic effects in this human trial setting. It must be noted that this evidence involves multi-ingredient preparations; the specific contribution of E. ribes cannot be isolated from these results.

5.7 Antimicrobial, Antifungal, and Antibacterial Activity

Evidence strength: Predominantly in vitro; no clinical trials

Embelin exhibits wide-ranging activities including antibacterial (Chitra et al., 2003). The essential oils/extracts and isolated chemical constituents of E. ribes exhibited antifungal and antibacterial activity among other promising pharmacological effects. These findings are derived from laboratory studies, and no controlled human clinical trials testing antimicrobial applications of E. ribes or embelin have been identified.

5.8 Neuroprotective Activity (Cerebral Ischemia)

Evidence strength: Animal models only

The neuroprotective effect of the aqueous extract of Embelia ribes was evaluated in focal ischemic brain; adult male Wistar albino rats were fed with the aqueous extract at 100 and 200 mg/kg (p.o.) for 30 days. Animals treated with the aqueous extract of Embelia ribes had a significant (P < 0.01) increase in post-stroke grip strength activity.

6. Body Systems and Health Areas

The essential oils/extracts and isolated chemical constituents of E. ribes have been studied in relation to antioxidant activity, wound healing, antidiabetic, central nervous system (CNS)-related disease, antiviral, antiobesity, cardioprotective, antifungal, antibacterial, and antifertility activity.

Gastrointestinal system: Anthelmintic, carminative, digestive, laxative, appetite-stimulating. Traditional use as an antiparasitic is among the most historically prominent.
Metabolic / Endocrine system: Antidiabetic and antidyslipidemic activity demonstrated in animal models.
Cardiovascular system: Cardioprotective effects against experimentally induced myocardial injury in animals.
Central nervous system: Anticonvulsant, anxiolytic, antidepressant, neuroprotective, and anti-amnesic effects documented in preclinical models.
Oncology / cell biology: Apoptosis induction via XIAP/NF-κB/p38 MAPK pathways studied extensively in cancer cell lines.
Reproductive system: Antifertility and antispermatogenic effects documented in animal models; limited human data from multi-herb formulations.
Integumentary (skin): Traditional use for fungal and skin diseases; antimicrobial activity in vitro.
Immune / inflammatory system: Anti-inflammatory mechanisms via TNF-α, NF-κB, and COX pathway modulation.

7. Dosage Forms and Reported Dosages

No standardized human dosage guidelines have been established by recognized pharmacopoeial or regulatory bodies for Embelia ribes or embelin as a standalone supplement. The following dosages derive entirely from the specific studies cited above:

In a rat study of antidyslipidemic activity, ethanolic extract was administered orally at 200 mg/kg for 20 days in STZ-induced diabetic rats.
In a cerebral ischemia neuroprotection study, the aqueous extract was administered at 100 and 200 mg/kg p.o. for 30 days in Wistar rats.
In a Huntington's disease model, embelin was pretreated in adult Wistar rats at doses of 10 and 20 mg/kg p.o. for a week.
In the anxiolytic study, embelin was tested at 2.5 and 5 mg/kg in animal models.
In human gastric carcinoma cell line work, embelin was applied at concentrations of 5, 10, and 15 µM on days 1, 3, and 5 (in vitro).
In the human Pippalyadi yoga study (a multi-herb formulation containing E. ribes), the composite preparation was administered orally at 1 gm/day in 254 women.
In a male antifertility animal study, embelin was administered subcutaneously at 0.3, 0.4, and 0.5 mg/kg body weight for 35 days.

Traditional Ayurvedic sources describe the use of approximately 3 grams of Embelia ribes powder with honey twice a day for intestinal worm treatment, though this traditional dosage has not been validated in controlled clinical trials.

8. Safety Considerations and Interactions

8.1 Reproductive Toxicity

Some reports have pointed out that embelin may affect embryonic development, and classified embelin as "reproductive toxicity, category 2" because of its being "suspected of damaging fertility or the unborn child." This classification is consistent with the extensive antifertility literature on the compound.

8.2 Acute Toxicity Profile in Animals

Acute toxicity studies in mice showed that oral administration of 50 or 100 mg/kg embelin had no significant changes in body weight, mortality, or any obvious toxic effect at those doses. Its administration in female cyclic rats at a dose of 120 mg/kg body weight did not cause any changes in the weight of liver, kidney, or spleen.

8.3 Antifertility and Hormonal Effects

When incorporated into the diet of female rats at both 10% and 20% dose levels, 62% antifertility activity was observed, with the diestrous phase prolonged within 2 weeks of treatment in the majority of these animals. The documented antifertility and anti-androgenic properties of the plant and embelin are relevant safety considerations in any population of reproductive age.

8.4 Bioavailability Limitation

The hydrophobic nature of embelin leads to poor absorption and limits its therapeutic potential, a factor that has been highlighted as a key limitation to translating preclinical findings into clinical practice.

8.5 Adulteration and Misidentification

Misidentification and adulteration in the market further threaten both the survival of E. ribes as a species and the quality of commercial preparations. This is a practically significant safety concern, as adulterated products may have different safety and efficacy profiles.

8.6 Status of Human Safety Evidence

To investigate the efficacy and safety profile of E. ribes, further high-quality preclinical studies using advanced methodologies are required. No formal, published Phase I or Phase II human safety trials of embelin or standardized E. ribes extract were identified in the reviewed literature.

Summary of Evidence Quality

The essential oils/extracts and isolated chemical constituents of E. ribes have exhibited antioxidant, wound healing, antidiabetic, CNS-related, antiviral, antiobesity, cardioprotective, antifungal, antibacterial, and antifertility activity in preclinical settings. The translation between traditional applications and modern medicine may make E. ribes a promising target for innovative medication; however, further high-quality preclinical studies using advanced methodologies are required to investigate its efficacy and safety profile. The entire body of mechanistic and pharmacological evidence currently rests on cell-line, animal, and zebrafish studies. With limited exceptions involving multi-herb Ayurvedic formulations, robust randomized controlled human clinical trial data are lacking for all investigated indications.

References

Health Conditions

Health conditions that Embelia may help support.

No conditions available.

Body Systems

Body systems that Embelia may help support.

No body systems available.